Oral Solid Dosage Pharmaceutical Market

Oral Solid Dosage Pharmaceutical Market Outlook (2022-2032)

The global oral solid dosage pharmaceutical market was valued at US$ 524.6 billion in 2021 and is expected to top US$ 1.03 trillion in value by the end of 2032, expanding rapidly at a CAGR of 6.4% over the 2022-2032 study period.

Revenue from the sales of oral solid dosage pharmaceuticals accounted for 23.8% share of the global pharmaceutical drug delivery market in 2021.

Data Points	Market Insights
Oral Solid Dosage Pharmaceutical Market Size (2021)	US$ 524.6 Billion
Estimated Market Value (2022)	US$ 555.3 Billion
Forecasted Market Value (2032)	US$ 1.03 Trillion
Global Market Growth Rate (2022-2032)	6.4% CAGR
East Asia Market Share (2021)	14.6%
East Asia Market Growth Rate (2022-2032)	7.4% CAGR
China Market Growth Rate (2022-2032)	8.3% CAGR
Share of Top 5 Countries	62.1%
Key Market Players	AstraZeneca Plc. Bristol-Myers Squibb Company Eli Lilly and Company Gilead Sciences Merck & Co. Inc Novartis AG Pfizer Inc. AbbVie Inc. Boehringer Ingelheim GmbH Hoffman-La-Roche Ltd. Johnson & Johnson Biogen Inc. Bayer AG Teva Pharmaceuticals Amgen Inc. Takeda Pharmaceutical Company Ltd. Otsuka Pharmaceutical Co., Ltd. Astellas Pharma Inc. Others

Oral solid dosage pharmaceuticals are final medication products that are consumed orally, broken down in the digestive tract, and then absorbed into the bloodstream. Oral solid doses are less expensive and simpler to produce than other dosage forms. They also provide important advantages such as trouble-free transport, packaging, and greater chemical & physical stability.

Low production cost is also contributing to market growth, especially in developing nations such as India due to collaborations with small-scale and medium-scale manufacturers. The production cost of oral solid dosage pharmaceuticals is low in India due to low and competitive land rates, availability of cheap labor, low-cost utilities, and affordable equipment. In developing regions, the labor cost is approximately 60% lower than in developed countries.

Oral Solid Dosage Pharmaceutical Demand Analysis (2012-2021) Compared to Market Outlook (2022-2032)

The global oral solid dosage drugs market expanded at a CAGR of 5.8% over the last nine years.

Manufacturers are involved in developing new oral solid formulations of drugs to improve drug efficacy and enhance outcomes. New formulation designs are preferred by leading manufacturers for implementing a patient-centric approach to efficiently improve solid oral dosage formulation (SODF) administration in older patient populations.

Rise of usability and patient compliance is also a key aspect driving global demand for oral solid dosage medications and this is a key concern for drug producers. Modified release (MR) oral solid dosage solutions are experiencing a sharp increase in demand due to growing patient-centric drug demand.

By sustaining therapeutic blood concentrations for a longer period, modified release medications can prolong the time a medicine is active in the body. It is possible to postpone the effect until a medication reaches a particular location by using unique coatings.

There is a large number of products in the pipeline in the form of oral solid dosages with improved efficacy and outcomes. Various research institutions and companies are involved in the drug discovery process to expand the market for oral solid dosage pharmaceuticals.

• For instance, Assembly Biosciences sponsored “A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults” for chronic Hepatitis B. This was in phase 1 of clinical trials as of January 2021.

Similarly, there are many other studies taking place related to oral solid dosage medicines to develop better drugs for various disease conditions. When these studies become successful and gain approval for commercialization, they will benefit companies by adding new segments to portfolios and generating more revenue.

Fact.MR, a market research and competitive intelligence provider, predicts that the global oral solid dosage pharmaceutical market will expand at a CAGR of 6.2% over the forecast period (2022-2032).

What’s Mainly Driving Demand for Oral Solid Dosage Pharmaceuticals?

“Ease of Administration and Improved Patient Compliance”

Oral solid dosage pharmaceuticals are very convenient dosage forms with excellent bioavailability. Few oral solid dosage forms such as chewable tablets are gaining popularity at a high pace because they are user-friendly and convenient alternatives to conventional tablets. These have various other advantages such as less pain, ease of ingestion, and variety in accommodating various types of drugs.

Patient compliance, non-invasiveness, and ease of drug administration are factors that make oral solid dosage the most preferred dosage form. It is most commonly used for those conditions where the drug needs to be administered repeatedly and for a prolonged period. Apart from convenience and affordability, it is the safest form of drug dosage.

Manufacturers of oral solid drugs can attain considerable bioavailability by implementing cutting-edge drug delivery technology methods. For instance, tailored drug delivery and dose forms with prolonged release increase the bioavailability of medications and decrease the need for repeated medication administration.

How is Oral Solid Dosage Pharmaceutical Market Growth Being Stunted?

“Difficulty in Oral Delivery Biologics Limiting Market Growth”

Currently, biologics are one of the most promising candidates for therapy, but their delivery is difficult due to the size of their large and complex molecules. There are various challenges in the oral delivery of solid dosage drugs. The most prominent challenge of biologics oral delivery is the harsh acidic environment of the gastrointestinal tract, which contains enzymes intended to break down molecules.

In addition, biologics or macromolecules have to pass multiple layers lining the track to reach the systemic distribution, which results in a lower bioavailability of drugs. Demand for macromolecular drugs such as biologics is increasing rapidly with the increasing prevalence of chronic diseases such as diabetes.

Apart from this, low R&D expenditure in low- and middle-income countries is also restricting the growth of the market. High-income countries have realized the importance of R&D and have invested enormously in the sector. Emerging nations, however, are still far behind in recognizing the potential advantages that R&D could provide for economic expansion and national advancement.

• According to a research article in Frontiers in Research Metrics and Analytics forum, global R&D spending was US$ 1.7 trillion in 2019. Around 80% of this share comes from just ten countries.

Country-wise Insights

What is the U.S. Market Stance for Oral Solid Dosage Pharmaceuticals?

The U.S. accounted for 93.6% of the North American oral solid dosage pharmaceutical market share in 2021 owing to the increasing number of oral solid dosage drug approvals in the country.

Approvals by the U.S. FDA are increasing and resulting in more products being launched, making the U.S a high revenue-generating country.

• For instance, The U.S. Food and Drug Administration (FDA) authorized 48 new medicines in 2019. 54% of these new FDA-approved medications were oral solid dosage products. It constituted 19 in the pills form and 7 in the capsules form.

Also, the rise in awareness about health supplements, which generally come in tablets or capsules, offers lucrative opportunities for the U.S. market for oral solid dosage pharmaceuticals.

Why is Germany a Lucrative Market for Oral Solid Dosage Drugs?

Germany accounted for 19.9% share in the Europe oral solid dosage pharmaceutical market in 2021.

Heart disease is one of the leading causes of death in Germany. Oral solid dosages are most commonly used for the treatment of heart diseases - use of Lotensin - benazepril (Rx) for the management of high blood pressure.

• According to the World Health Organization, circulatory diseases accounted for 37% of all deaths in Germany in 2019.

What are the Factors Fueling Demand for Oral Solid Dosage Solutions in China?

China accounted for 51.4% of the East Asia oral solid dosage pharmaceutical market at the end of 2021.

China provides medicines at very low prices due to the cost-effective drug production in the country. Low production cost is possible because top pharmaceutical companies have lowered the cost of drugs in China by an average of 61%. This is primarily due to the revised reimbursement scenario in the country.

For instance, pharmaceutical companies such as Roche and Novartis have decided to lower the cost of several of their newest medications in China. This helps the country in selling a high number of drugs to patients and increasing its presence in the global market.

Category-wise Insights

Why is Demand for Tablets So High?

By dosage form, tablets accounted for the highest market share of 53.1% in 2021. The segment is expected to expand at 7.1% CAGR over the forecast period.

The most popular form of an oral solid dose is a tablet. These are affordable, secure, and efficient means of delivering oral medications, which is why their demand is so high in the market.

Which Drug Release Mechanism is Most Common in the Market?

By drug release mechanism, immediate release contributed the highest market share of 57.9% in 2021. The segment is expected to expand at 6.1% CAGR over the decade.

Immediate release tablets/capsules held the highest market share in 2021 because these are used to release the medication for absorption and subsequent pharmacologic action. It results in quick action and early pain relief.

Competitive Landscape

Key manufacturers of oral solid dosage pharmaceutical products are actively focusing on the expansion of their portfolios by gaining approvals for their new products and entering into partnerships with leading companies.

• In March 2022, AstraZeneca received clearance from the EU government for selling Evusheld long-acting antibody combinations for the prevention of COVID-19 in a broad population.
• In June 2022, Bristol Myers Squibb announced a definitive merger agreement for acquiring Turning Point Therapeutics. This acquisition will improve the oncology medicines segment of BMS because Turning Point Therapeutics is a clinical-stage precision oncology company.

Similarly, recent developments related to companies manufacturing oral solid dosage pharmaceuticals have been tracked by the team at Fact.MR, which are available in the full report.

Key Segments in Oral Solid Dosage Pharmaceutical Industry Research

• By Dosage Form :

  • Tablets
    • Conventional/Immediate Release
    • Modified Release
    • Chewable Tablets
    • Effervescent Tablets
  • Capsules
    • Hard Gelatin Capsules
    • Soft Gelatin Capsules
    • Others
  • Powders & Granules
  • Lozenges & Pastilles
  • Gummies

• By Drug Release Mechanism :

  • Immediate Release
  • Delayed Release
  • Controlled Release

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Hypermarkets / Supermarkets

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)